0001610717-24-000097.txt : 20240228
0001610717-24-000097.hdr.sgml : 20240228
20240228173116
ACCESSION NUMBER: 0001610717-24-000097
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240227
FILED AS OF DATE: 20240228
DATE AS OF CHANGE: 20240228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Symons Julian A.
CENTRAL INDEX KEY: 0001824727
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 24697319
MAIL ADDRESS:
STREET 1: C/O ALIGOS THERAPEUTICS, INC.
STREET 2: ONE CORPORATE DRIVE, 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2024-02-27
0001799448
Aligos Therapeutics, Inc.
ALGS
0001824727
Symons Julian A.
C/O ALIGOS THERAPEUTICS, INC.
ONE CORPORATE DRIVE, 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
true
See Remarks
false
Stock Option (Right to Buy)
16.18
2024-02-27
4
D
0
200000
0
D
2021-01-01
2030-12-01
Common Stock
200000
0
D
Stock Option (Right to Buy)
3.06
2024-02-27
4
D
0
105000
0
D
2022-03-04
2032-02-04
Common Stock
105000
0
D
Stock Option (Right to Buy)
3.06
2024-02-27
4
D
0
26250
0
D
2025-02-04
2032-02-04
Common Stock
26250
0
D
Stock Option (Right to Buy)
0.96
2024-02-28
4
A
0
58822
0
A
2030-12-01
Common Stock
58822
58822
D
Stock Option (Right to Buy)
0.96
2024-02-28
4
A
0
74998
0
A
2032-02-04
Common Stock
74998
74998
D
Stock Option (Right to Buy)
0.96
2024-02-28
4
A
0
18750
0
A
2032-02-04
Common Stock
18750
18750
D
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 200,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 58,822 shares, having an exercise price of $0.96 per share.
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share.
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share.
The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.
The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date.
Executive Vice President, Chief Scientific Officer
/s/ Lesley Ann Calhoun, as attorney-in fact for Julian A. Symons
2024-02-28